Trial
NCT04569084
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tanabe Pharma America, Inc.
Collaborators
—
Condition
ALS
Intervention
MT-1186
Why stopped
Futility was met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22